AGN - Argenica Therapeutics with Proactive at the ASX Small and Mid-Cap Conference
(NewsDirect)
Argenica Therapeutics Ltd (ASX: AGN) CEO Liz Dallimore speaks withProactive from the ASX Small and Mid-Cap Conference March 2023. Thecompany is developing novel therapeutics to reduce brain tissue deathafter stroke and other types of brain injury and neurodegenerativediseases to improve patient outcomes. Its lead neuroprotective peptidecandidate, ARG-007, has been demonstrated to improve outcomes inpre-clinical stroke models, traumatic brain injury (TBI) and hypoxicischaemic encephalopathy (HIE).
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.